

MarÃ-a Isabel Lucena GonzÃ¡lez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2196569/publications.pdf>

Version: 2024-02-01

164
papers

9,386
citations

43973

48
h-index

40881

93
g-index

176
all docs

176
docs citations

176
times ranked

6180
citing authors

#	ARTICLE	IF	CITATIONS
1	Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e548-e563.	2.4	21
2	A revised electronic version of RUCAM for the diagnosis of DILI. <i>Hepatology</i> , 2022, 76, 18-31.	3.6	52
3	Heterologous COVID-19 Vaccination in Spain: A Case Study of Individual Autonomy in the Real World. <i>Value in Health</i> , 2022, 25, 770-772.	0.1	5
4	Reply. <i>Hepatology</i> , 2022, 76, E28-E28.	3.6	1
5	Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. <i>Biomedicines</i> , 2022, 10, 55.	1.4	4
6	Reply. <i>Hepatology</i> , 2022, 76, E73-E73.	3.6	0
7	Methionine Cycle Rewiring by Targeting miR-873-5p Modulates Ammonia Metabolism to Protect the Liver from Acetaminophen. <i>Antioxidants</i> , 2022, 11, 897.	2.2	3
8	N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	18
9	Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports. <i>Hepatology Communications</i> , 2022, 6, 1895-1909.	2.0	15
10	Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury. <i>Pharmacological Research</i> , 2022, 182, 106348.	3.1	29
11	Profile of herbal and dietary supplements induced liver injury in Latin America: A systematic review of published reports. <i>Phytotherapy Research</i> , 2021, 35, 6-19.	2.8	13
12	Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1125-1135.	2.3	31
13	Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young to the Old. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1147-1158.	2.3	16
14	Genetic risk factors in the development of idiosyncratic drug-induced liver injury. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 153-169.	1.5	22
15	Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. <i>Pharmacological Research</i> , 2021, 164, 105404.	3.1	29
16	Characterizing Highly Cited Papers in Mass Cytometry through H-Classics. <i>Biology</i> , 2021, 10, 104.	1.3	6
17	Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. <i>Antioxidants</i> , 2021, 10, 390.	2.2	64
18	Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machine learning approach. <i>Archives of Toxicology</i> , 2021, 95, 1793-1803.	1.9	3

#	ARTICLE	IF	CITATIONS
19	Serious liver injury induced by Nimesulide: an international collaborative study. Archives of Toxicology, 2021, 95, 1475-1487.	1.9	7
20	Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. Journal of Hepatology, 2021, 75, 86-97.	1.8	72
21	Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. Journal of Hepatology, 2021, 75, 333-341.	1.8	23
22	P041 Tandem mass tag-based quantitative proteomic profiling identifies novel putative serum biomarkers for the diagnosis of drug-induced liver injury in patients. , 2021, , .		1
23	Lymphocyte Profile and Immune Checkpoint Expression in Drug-Induced Liver Injury: An Immunophenotyping Study. Clinical Pharmacology and Therapeutics, 2021, 110, 1604-1612.	2.3	15
24	Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]. Journal of Hepatology, 2021, 75, 935-959.	1.8	66
25	Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions. Journal of Clinical Medicine, 2021, 10, 5317.	1.0	3
26	Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction. Acta Pharmaceutica Sinica B, 2021, 11, 3685-3726.	5.7	27
27	Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry. Liver International, 2020, 41, 1523-1531.	1.9	10
28	Drug induced liver injury: an update. Archives of Toxicology, 2020, 94, 3381-3407.	1.9	125
29	Drug-induced liver injury in older people. The Lancet Gastroenterology and Hepatology, 2020, 5, 862-874.	3.7	42
30	Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations. Genes, 2020, 11, 1275.	1.0	6
31	Differential hepatoprotective role of the cannabinoid CB ₁ and CB ₂ receptors in paracetamol-induced liver injury. British Journal of Pharmacology, 2020, 177, 3309-3326.	2.7	13
32	Systematic review: ibuprofen-induced liver injury. Alimentary Pharmacology and Therapeutics, 2020, 51, 603-611.	1.9	32
33	Reply letter to “Editorial: bodybuilders beware”. Alimentary Pharmacology and Therapeutics, 2019, 50, 473-473.	1.9	0
34	Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure. Gastroenterology, 2019, 157, 552-568.	0.6	85
35	FRI-077-Influence of drug categorization according to labelling information in the phenotypic presentation of drug-induced liver injury (DILI): An analysis in the Spanish DILI registry. Journal of Hepatology, 2019, 70, e418.	1.8	1
36	FRI-078-Serious liver injury induced by nimesulide: An international collaboration reporting 57 cases. Journal of Hepatology, 2019, 70, e418-e419.	1.8	0

#	ARTICLE	IF	CITATIONS
37	Drug-induced liver injury. <i>Nature Reviews Disease Primers</i> , 2019, 5, 58.	18.1	409
38	EASL Clinical Practice Guideline: Occupational liver diseases. <i>Journal of Hepatology</i> , 2019, 71, 1022-1037.	1.8	22
39	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 245-253.	2.3	58
40	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1028-1036.	2.3	52
41	Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice. <i>Seminars in Liver Disease</i> , 2019, 39, 381-394.	1.8	20
42	Deficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease. <i>Cell</i> , 2019, 177, 881-895.e17.	13.5	209
43	Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. <i>United European Gastroenterology Journal</i> , 2019, 7, 825-837.	1.6	29
44	Next-Generation Sequencing of PTGS Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury. <i>Frontiers in Genetics</i> , 2019, 10, 134.	1.1	10
45	The usefulness of TV medical dramas for teaching clinical pharmacology: A content analysis of <i>House, M.D.</i> . <i>Educacion Medica</i> , 2019, 20, 295-303.	0.3	4
46	When the Creation of a Consortium Provides Useful Answers: Experience of The Latin American DILI Network (LATINDILIN). <i>Clinical Liver Disease</i> , 2019, 13, 51-57.	1.0	21
47	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019, 156, 1707-1716.e2.	0.6	97
48	Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach. <i>Current Pharmaceutical Design</i> , 2019, 25, 3855-3871.	0.9	13
49	Hepatic Damage by Natural Remedies. <i>Seminars in Liver Disease</i> , 2018, 38, 021-040.	1.8	33
50	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1495-1502.	2.4	83
51	Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 477-496.	0.1	2
52	Sulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 843-853.	2.3	18
53	High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 292-294.	2.4	18
54	Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors. , 2018, , 625-650.		0

#	ARTICLE	IF	CITATIONS
55	The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury. <i>Liver International</i> , 2018, 39, 401-410.	1.9	10
56	Drug-induced liver injury: a safety review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 795-804.	1.0	31
57	DRESS cases included in the Spanish and Latin-American DILI registries: clinical phenotype and outcome. <i>Journal of Hepatology</i> , 2018, 68, S601.	1.8	3
58	Data mining techniques to identify potential clinical presentation modulators in drug-induced liver injury. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-9-13.	0.0	0
59	A New Hepatoprotective Effect of Statins: Are They Always Safe for the Liver?. <i>American Journal of Gastroenterology</i> , 2017, 112, 384-385.	0.2	3
60	Data Mining for Possible Drug-Host Interplay in Clinical Phenotypes of Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2017, 152, S1080-S1081.	0.6	0
61	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017, 152, 1078-1089.	0.6	174
62	Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences. <i>Current Hepatology Reports</i> , 2017, 16, 286-292.	0.4	3
63	Jnk2 is indispensable in murine and human Ibuprofen-induced acute liver failure. <i>Journal of Hepatology</i> , 2017, 66, S400.	1.8	0
64	Drug-induced liver and skin reactions: In need of a consensus definition. <i>Hepatology</i> , 2017, 65, 391-391.	3.6	3
65	Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury. <i>Liver International</i> , 2017, 37, 132-140.	1.9	25
66	The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury. <i>Nature Communications</i> , 2017, 8, 2068.	5.8	77
67	Acetaminophen-Induced Liver Injury Alters the Acyl Ethanolamine-Based Anti-Inflammatory Signaling System in Liver. <i>Frontiers in Pharmacology</i> , 2017, 8, 705.	1.6	18
68	A morphological method for ammonia detection in liver. <i>PLoS ONE</i> , 2017, 12, e0173914.	1.1	28
69	The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. <i>International Journal of Molecular Sciences</i> , 2016, 17, 313.	1.8	63
70	Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. <i>International Journal of Molecular Sciences</i> , 2016, 17, 714.	1.8	69
71	Biomarkers in DILI: One More Step Forward. <i>Frontiers in Pharmacology</i> , 2016, 7, 267.	1.6	52
72	Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish Patients. <i>Frontiers in Pharmacology</i> , 2016, 7, 280.	1.6	3

#	ARTICLE	IF	CITATIONS
73	Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 414-422.	0.7	21
74	Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases. <i>Liver International</i> , 2016, 36, 302-310.	1.9	39
75	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. <i>Journal of Hepatology</i> , 2016, 65, 532-542.	1.8	115
76	Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 507-516.	5.5	78
77	Hepatotoxicity Associated with Non-Steroidal Anti-Inflammatory Drugs. A Comparative Analysis among Ibuprofen, Diclofenac and Nimesulide from the Spanish and Latin-American DILI Registries. <i>Journal of Hepatology</i> , 2016, 64, S239-S240.	1.8	0
78	Hepatotoxicity induced by coxibs: how concerned should we be?. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1463-1475.	1.0	26
79	Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions. <i>Drug Safety</i> , 2016, 39, 925-943.	1.4	30
80	Pro-Euro-DILI Registry: A Collaborative Effort to Enhance the Understanding of DILI. <i>Journal of Hepatology</i> , 2016, 64, S293-S294.	1.8	8
81	“Drug-Induced Liver Injury Clinical Consortia: a global research response for a worldwide health challenge”. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 589-593.	1.5	17
82	P1097 : Distinguishing drug induced autoimmune hepatitis from idiopathic autoimmune hepatitis. <i>Journal of Hepatology</i> , 2015, 62, S761.	1.8	1
83	Hepatotoxicity related to Herbals and Dietary Supplements (HDS): a cause for concern. <i>Clinical Therapeutics</i> , 2015, 37, e123.	1.1	0
84	Metabolic risk factors affect clinical Phenotype and outcome of Hepatotoxicity (DILI). <i>Clinical Therapeutics</i> , 2015, 37, e126-e127.	1.1	0
85	Clinical Networks And Consortia In Drug-Induced Liver Injury (DILI): An Opportunity For Advancing Safety Science. <i>Clinical Therapeutics</i> , 2015, 37, e166.	1.1	0
86	Reply. <i>Gastroenterology</i> , 2015, 148, 452-453.	0.6	0
87	Acute liver failure following atorvastatin dose escalation: Is there a threshold dose for idiosyncratic hepatotoxicity?. <i>Journal of Hepatology</i> , 2015, 62, 751-752.	1.8	31
88	Mitofusin 2 as a Driver That Controls Energy Metabolism and Insulin Signaling. <i>Antioxidants and Redox Signaling</i> , 2015, 22, 1020-1031.	2.5	69
89	P1098 : Influence of metabolic risk factors in hepatotoxicity (DILI) phenotype and outcome. <i>Journal of Hepatology</i> , 2015, 62, S761-S762.	1.8	0
90	Drug-induced liver injury: Interactions between drug properties and host factors. <i>Journal of Hepatology</i> , 2015, 63, 503-514.	1.8	319

#	ARTICLE	IF	CITATIONS
91	The value of serum aspartate aminotransferase and gamma-glutamyl transpeptidase as biomarkers in hepatotoxicity. <i>Liver International</i> , 2015, 35, 2474-2482.	1.9	47
92	Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 116-125.	1.9	95
93	Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <i>Annals of Hepatology</i> , 2014, 13, 231-239.	0.6	27
94	Hepatotoxicity Induced by Herbal and Dietary Supplements. <i>Seminars in Liver Disease</i> , 2014, 34, 172-193.	1.8	77
95	Reply. <i>Gastroenterology</i> , 2014, 147, 1442.	0.6	0
96	Mechanisms of drug-induced liver injury. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2014, 14, 286-292.	1.1	86
97	Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2014, 147, 109-118.e5.	0.6	248
98	P310 ANABOLIC ANDROGENIC STEROIDS (AAS) ILLICIT USE IS A RAPIDLY GROWING CAUSE OF DRUG-INDUCED LIVER INJURY (DILI): A PROSPECTIVE SERIES FROM THE SPANISH-LATIN-AMERICAN DILI REGISTRY. <i>Journal of Hepatology</i> , 2014, 60, S169.	1.8	0
99	P309 PROGNOSTIC MODEL FOR PREDICTING DRUG-INDUCED ACUTE LIVER FAILURE. <i>Journal of Hepatology</i> , 2014, 60, S169.	1.8	0
100	Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort. <i>PLoS ONE</i> , 2014, 9, e94675.	1.1	19
101	Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. <i>World Journal of Hepatology</i> , 2014, 6, 160.	0.8	105
102	Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. <i>Annals of Hepatology</i> , 2014, 13, 231-9.	0.6	9
103	Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury. <i>Liver International</i> , 2013, 33, 1378-1385.	1.9	38
104	Use of Drugs Related to the Treatment of Diabetes Mellitus and Other Cardiovascular Risk Factors in the Spanish Population. The Di@bet.es Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 854-863.	0.4	5
105	PP022-Variations in drug-induced liver injury (DILI) between different prospective dili registries. <i>Clinical Therapeutics</i> , 2013, 35, e24.	1.1	4
106	PP025-Improving hy's law definition to better predict the risk of developing acute liver failure in drug-induced liver injury (DILI). <i>Clinical Therapeutics</i> , 2013, 35, e25.	1.1	0
107	518 THE SPANISH-LATIN AMERICAN DILI NETWORK: PRELIMINARY RESULTS FROM A COLLABORATIVE STRATEGIC INITIATIVE. <i>Journal of Hepatology</i> , 2013, 58, S212-S213.	1.8	4
108	Causality Assessment. , 2013, , 287-302.		1

#	ARTICLE	IF	CITATIONS
109	HLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatotoxicity. <i>PLoS ONE</i> , 2013, 8, e68111.	1.1	81
110	Indacaterol-induced severe constipation and abdominal pain: is there a role for colonic α -adrenoceptors?. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013009568-bcr2013009568.	0.2	3
111	Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 784-795.	0.7	108
112	Factores de riesgo y mecanismos de toxicidad hepática. Daño hepático inducido por medicamentos y tóxicos (excluido el alcohol). <i>Medicine</i> , 2012, 11, 573-580.	0.0	1
113	Un caso de hepatopatía tóxica. <i>Medicine</i> , 2012, 11, 624.e1-624.e4.	0.0	0
114	Trends in Qualifying Biomarkers in Drug Safety. Consensus of the 2011 Meeting of the Spanish Society of Clinical Pharmacology. <i>Frontiers in Pharmacology</i> , 2012, 3, 2.	1.6	11
115	Genetic variations in drug-induced liver injury (DILI): resolving the puzzle. <i>Frontiers in Genetics</i> , 2012, 3, 253.	1.1	12
116	Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. <i>Frontiers in Genetics</i> , 2012, 3, 273.	1.1	23
117	Syndrome of inappropriate antidiuresis in doxylamine overdose. <i>BMJ Case Reports</i> , 2012, 2012, bcr-2012-007428-bcr-2012-007428.	0.2	7
118	Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 817-828.	1.5	48
119	Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. <i>Gastroenterology</i> , 2011, 141, 338-347.	0.6	412
120	Recurrent Drug-Induced Liver Injury (DILI) with different drugs in the Spanish Registry: The dilemma of the relationship to autoimmune hepatitis. <i>Journal of Hepatology</i> , 2011, 55, 820-827.	1.8	89
121	Causality assessment methods in drug induced liver injury: Strengths and weaknesses. <i>Journal of Hepatology</i> , 2011, 55, 683-691.	1.8	164
122	486 IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI) IN PATIENTS WITH PRE-EXISTING LIVER DISEASE: AN ANALYSIS OF THE CASES INCLUDED IN THE SPANISH DILI REGISTRY. <i>Journal of Hepatology</i> , 2011, 54, S199.	1.8	1
123	Drug-Induced Autoimmune-Like Hepatitis: A Diagnostic Challenge. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2501-2503.	1.1	16
124	Continuous reporting of new cases in Spain supports the relationship between Herbalife® products and liver injury. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1080-1087.	0.9	34
125	The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. <i>Hepatology</i> , 2011, 54, 931-939.	3.6	279
126	Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. <i>Hepatology</i> , 2010, 52, 303-312.	3.6	97

#	ARTICLE	IF	CITATIONS
127	Reflections on Running Training Workshops for Research Ethics Committee Members in Spain Between 2001 and 2008. <i>Croatian Medical Journal</i> , 2010, 51, 552-559.	0.2	3
128	Antibiotic-Induced Liver Toxicity: Mechanisms, Clinical Features and Causality Assessment. <i>Current Drug Safety</i> , 2010, 5, 212-222.	0.3	34
129	Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in Vigibase. <i>Drug Safety</i> , 2010, 33, 503-522.	1.4	142
130	1137 THE HLA CLASS I B*1801 ALLELE INFLUENCES HEPATOCELLULAR EXPRESSION OF AMOXICILLIN-CLAVULANATE LIVER DAMAGE AND OUTCOME IN SPANISH PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S439.	1.8	5
131	Rechallenge in drug-induced liver injury: the attractive hazard. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 709-714.	1.0	47
132	Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute <i>Mycoplasma pneumoniae</i> infection. <i>Clinical Therapeutics</i> , 2009, 31, 1014-1019.	1.1	26
133	Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. <i>Hepatology</i> , 2009, 49, 2001-2009.	3.6	266
134	Reply. <i>Hepatology</i> , 2009, 49, 1777-1779.	3.6	0
135	Corrigendum to "Analysis of IL-10, IL-4 and TNF- α polymorphisms in drug-induced liver injury (DILI) and its outcome" [<i>J Hepatol</i> 49 (2008) 107-114]. <i>Journal of Hepatology</i> , 2009, 50, 636.	1.8	1
136	Drug-induced liver injury: insights from genetic studies. <i>Pharmacogenomics</i> , 2009, 10, 1467-1487.	0.6	90
137	Pharmacogenomics in Drug Induced Liver Injury. <i>Current Drug Metabolism</i> , 2009, 10, 956-970.	0.7	70
138	Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. <i>Hepatology</i> , 2008, 48, 588-596.	3.6	181
139	Analysis of IL-10, IL-4 and TNF- α polymorphisms in drug-induced liver injury (DILI) and its outcome. <i>Journal of Hepatology</i> , 2008, 49, 107-114.	1.8	72
140	Idiosyncratic drug hepatotoxicity: a 2008 update. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 261-276.	1.3	18
141	Statins: Hepatic Disease and Hepatotoxicity Risk. <i>The Open Gastroenterology Journal</i> , 2008, 2, 18-23.	0.1	4
142	Genetic and Molecular Factors in Drug-Induced Liver Injury: A Review. <i>Current Drug Safety</i> , 2007, 2, 97-112.	0.3	26
143	Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). <i>British Journal of Pharmacology</i> , 2007, 150, 808-815.	2.7	44
144	Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: A prospective series from Spain. <i>Hepatology</i> , 2006, 44, 850-856.	3.6	143

#	ARTICLE	IF	CITATIONS
145	Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. <i>Hepatology</i> , 2006, 44, 1581-1588.	3.6	267
146	Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report. <i>World Journal of Gastroenterology</i> , 2006, 12, 5244-6.	1.4	18
147	The administration of N-acetylcysteine causes a decrease in prothrombin time in patients with paracetamol overdose but without evidence of liver impairment. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 59-63.	0.8	16
148	Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. <i>Gastroenterology</i> , 2005, 129, 512-521.	0.6	847
149	Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. <i>Gastroenterology</i> , 2005, 129, 512-521.	0.6	595
150	Is the Naranjo Probability Scale Accurate Enough to Ascertain Causality in Drug-Induced Hepatotoxicity?. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1540-1541.	0.9	19
151	HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. <i>Hepatology</i> , 2004, 39, 1603-1612.	3.6	134
152	Causality assessment in drug-induced hepatotoxicity. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 329-344.	1.0	70
153	Drug use for non-hepatic associated conditions in patients with liver cirrhosis. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 71-76.	0.8	30
154	Antidepressant-induced hepatotoxicity. <i>Expert Opinion on Drug Safety</i> , 2003, 2, 249-262.	1.0	75
155	Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 887-890.	0.8	45
156	Chronic Hepatitis C, Ibuprofen, and Liver Damage. <i>American Journal of Gastroenterology</i> , 2002, 97, 1854-1855.	0.2	19
157	Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 435-440.	0.8	72
158	Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2002, 40, 2-8.	0.3	92
159	Comparison of two clinical scales for causality assessment in hepatotoxicity. <i>Hepatology</i> , 2001, 33, 123-130.	3.6	240
160	Chronic liver injury related to use of benzazepam: an unusual instance of benzodiazepine hepatotoxicity. <i>Digestive Diseases and Sciences</i> , 2000, 45, 1400-1404.	1.1	28
161	Trovafloxacin-Induced Acute Hepatitis. <i>Clinical Infectious Diseases</i> , 2000, 30, 400-401.	2.9	91
162	Acute liver failure after treatment with nefazodone. <i>Digestive Diseases and Sciences</i> , 1999, 44, 2577-2579.	1.1	38

#	ARTICLE	IF	CITATIONS
163	Norfloxacin-Induced Cholestatic Jaundice. American Journal of Gastroenterology, 1998, 93, 2309-2311.	0.2	20
164	Effect of cyclosporin a on platelet aggregation and thromboxane/prostacyclin balance in a model of extrahepatic cholestasis in the rat. Thrombosis Research, 1996, 81, 367-381.	0.8	10